Bleomycin: A novel osteogenesis inhibitor of dental follicle cells via a TGF-β1/SMAD7/RUNX2 pathway.

Zhi-Zheng LiHai-Tao WangGrace Y LeeYing YangYan-Ping ZouBing WangChu-Jie GongYu CaiJian-Gang RenJi-Hong Zhao

Published in: British journal of pharmacology (2020)

SMAD7 was a negative regulator of osteogenic differentiation in DFCs through suppressing RUNX2 expression. Bleomycin or TGF-β1 inhibited osteogenic differentiation of DFCs via a TGF-β1/SMAD7/RUNX2 pathway. Our findings might be beneficial for enhancing the osteogenic activity of DFCs or inhibiting the eruption of undesirable teeth.

Keyphrases

transforming growth factor
epithelial mesenchymal transition
transcription factor
signaling pathway
mesenchymal stem cells
induced apoptosis
bone marrow
pulmonary fibrosis
poor prognosis
oxidative stress
endoplasmic reticulum stress
cell death
long non coding rna